Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AGS-8M4
- Development stage
- Phase 1
- Lead developer
- Astellas Pharma
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
AGS-8M4 is a humanized monoclonal antibody developed for the treatment of ovarian cancer. It targets the cell surface protein activator of G-proteins signaling 8 (AGS-8), acting as a surface antigen inhibitor with potential antineoplastic activity. The drug was originally developed by Agensys, which was acquired by Astellas Pharma. AGS-8M4 has been investigated in clinical trials including phase I and phase II studies but development for ovarian cancer has been suspended.
- Other names
- anti-AGS-8 monoclonal antibody AGS-8M4anti-AGS8 monoclonal antibody AGS-8M4anti-AGS 8 monoclonal antibody AGS-8M4
02
Targets
GPSM1 (Activator of G-protein signaling 8)
Beyond the preview
Go deeper on AGS-8M4.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AGS-8M4.